Olpasiran Shows Promise in Reducing High-Risk Cholesterol and Inflammation

**Olpasiran**, a small interfering RNA targeting lipoprotein(a) or Lp(a), has demonstrated a capacity to substantially lower this 'bad cholesterol' by over 95% in patients with cardiovascular conditions, as reported by Mount Sinai researchers in JAMA Cardiology. The trial, known as OCEAN(a)-DOSE, included 282 patients with elevated Lp(a) levels, which contribute to cardiovascular events such as heart attacks and strokes. Lp(a) acts much like LDL cholesterol but is even more potent on a per-particle basis. **Key findings** from the trial indicated that olpasiran effectively reduced not only Lp(a) levels but also oxidized phospholipids, known drivers of atherosclerosis. Importantly, whilst it showed no major effects on pro-inflammatory cytokines like interleukin-6, the trial confirmed olpasiran's safety profile was on par with placebos. This suggests a **promising new approach** to tackling cardiovascular diseases associated with Lp(a). The ongoing phase 3 trials aim to further elucidate these findings and refine patient selection for future treatment protocols.